The group could soon provide clarity on CTX112’s regulatory path.

The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.

A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.

Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.